These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1188 related articles for article (PubMed ID: 2138003)
1. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)]. Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003 [TBL] [Abstract][Full Text] [Related]
2. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia. McGovren JP Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690 [TBL] [Abstract][Full Text] [Related]
3. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin. Neil GL; Kuentzel SL; McGovren JP Cancer Treat Rep; 1979; 63(11-12):1971-8. PubMed ID: 526931 [TBL] [Abstract][Full Text] [Related]
4. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice. Dawson KM Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953 [TBL] [Abstract][Full Text] [Related]
5. [Antitumor spectrum of TUT-7 on rat ascitic hepatoma]. Satoh H; Taguchi H; Yahagi S Gan To Kagaku Ryoho; 1990 Feb; 17(2):287-91. PubMed ID: 2137321 [TBL] [Abstract][Full Text] [Related]
6. [Models of preclinical studies of anthracyclines]. Fizames C Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611 [TBL] [Abstract][Full Text] [Related]
7. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962 [TBL] [Abstract][Full Text] [Related]
9. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778 [TBL] [Abstract][Full Text] [Related]
10. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799 [TBL] [Abstract][Full Text] [Related]
11. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice. Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436 [TBL] [Abstract][Full Text] [Related]
13. Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture. Bhuyan BK; Blowers CL; Crampton SL; Shugars KD Cancer Res; 1981 Jan; 41(1):18-24. PubMed ID: 7448758 [TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873 [TBL] [Abstract][Full Text] [Related]
15. [The antitumor activity of intraperitoneally- or orally-administered etoposide in animals and its administration-schedule dependency]. Okamoto K; Nishikawa K; Seki T; Shibasaki C; Uchida T; Takahashi K Gan To Kagaku Ryoho; 1985 Dec; 12(12):2331-7. PubMed ID: 4073928 [TBL] [Abstract][Full Text] [Related]
16. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells. Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors. Furusawa S; Mian AM Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967 [TBL] [Abstract][Full Text] [Related]
18. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin. Chandrasekaran B; Dimling J; Capizzi RL Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640 [TBL] [Abstract][Full Text] [Related]
19. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Wallace RE; Murdock KC; Angier RB; Durr FE Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798 [TBL] [Abstract][Full Text] [Related]
20. Effects of 7-R-O-methylnogarol (menogaril) on L1210 cell progression in vitro and in vivo. Adams EG; Bhuyan BK Cancer Res; 1986 Dec; 46(12 Pt 1):6125-30. PubMed ID: 2946401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]